Skip to main content

TOP - Daily

The new healthcare law’s Preexisting Condition Insurance Plan (PCIP) program is providing insurance to thousands of people with high-risk preexisting conditions. The US Department of Health and Human Services recently reported how PCIP is helping to fill a void in the insurance market.

Read More ›

A recent study shows that women who received a combination breast cancer chemotherapy regimen referred to as CMF between 1976 and 1995 performed worse on cognitive tests compared with women who never had cancer. The subtle differences in performance were statistically significant and occurred primarily in word learning and memory and information processing speed.

The findings, published February 27 in the Journal of Clinical Oncology, indicate that cognitive problems may be observed 20 years following chemotherapy treatment.

Read More ›

Shortages of drugs used for treating patients with hematologic malignancies have recently become critical and life threatening. The following is a February 27, 2012, update on the status of hematologic drug shortages and helpful resources for pharmacists.

Limited Quantities of Daunorbucin Are Available

Read More ›

The first molecular test to help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy has been approved by the FDA.

Read More ›

Four new drugs could help change advanced prostate cancer from a terminal disease to a chronic illness, according to a prostate cancer expert in a recent review for the journal Oncology.

Read More ›

Medication errors are common among primary care providers; however, the number of mistakes could be reduced significantly with the use of in-house pharmacists.

A comprehensive study, led by Tony Avery, Professor of Primary Health Care in the School of Community Health Sciences at The University of Nottingham, involved at-risk patients in 72 general practices. Patients were taking the drugs most commonly and consistently associated with medication errors. Study results were published recently in The Lancet.

Read More ›

Many women endure hot flashes and night sweats following breast cancer treatment. British researchers are now saying that cognitive behavioral therapy (CBT) is an effective treatment for women experiencing these main symptoms of menopause.

Read More ›

A warning has been issued by the FDA regarding a counterfeit version of Avastin 400 mg/16 mL, which may have been purchased and utilized by medical practices in the United States. Chemical analyses of the imitation vials have confirmed the product lacks the active ingredient of Avastin, bevacizumab, which may have resulted in patients not receiving needed therapy.

Packages or vials may be counterfeit if:

Read More ›

A newly patented computerized system effectively chooses the right patient for the right clinical trial. The program quickly matches a registered patient’s molecular profile to a disease-targeting drug’s molecular design. According to the Moffit Cancer Center, the system will accelerate clinical trials and help reduce the time required for critical new drugs to reach the market.

Read More ›

Targeted drugs, such as gefitinib, might be more effective against non–small cell lung cancer (NSCLC) when combined with agents that block certain microRNAs, according to new research published in Nature Medicine.

Read More ›

Page 38 of 73